Skip to Content

Protagonist Therapeutics Inc PTGX

Morningstar Rating
$25.61 +0.39 (1.55%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PTGX is trading at a 41% discount.
Price
$25.46
Fair Value
$92.55
Uncertainty
Extreme
1-Star Price
$874.14
5-Star Price
$59.32
Economic Moat
Gwhdw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTGX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$25.22
Day Range
$24.7925.63
52-Week Range
$13.7233.34
Bid/Ask
$25.61 / $27.49
Market Cap
$1.49 Bil
Volume/Avg
452,407 / 665,166

Key Statistics

Price/Earnings (Normalized)
Price/Sales
24.24
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
112

Comparables

Valuation

Metric
PTGX
EQRX
ACLX
Price/Earnings (Normalized)
Price/Book Value
4.390.975.87
Price/Sales
24.2423.74
Price/Cash Flow
Price/Earnings
PTGX
EQRX
ACLX

Financial Strength

Metric
PTGX
EQRX
ACLX
Quick Ratio
16.5418.435.94
Current Ratio
16.7118.786.06
Interest Coverage
−23.39
Quick Ratio
PTGX
EQRX
ACLX

Profitability

Metric
PTGX
EQRX
ACLX
Return on Assets (Normalized)
−16.60%−15.72%−6.26%
Return on Equity (Normalized)
−18.20%−16.71%−12.08%
Return on Invested Capital (Normalized)
−23.45%−21.31%−13.11%
Return on Assets
PTGX
EQRX
ACLX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNdvhlxrvVpfv$550.4 Bil
VRTX
Vertex Pharmaceuticals IncMcsjlwtbLslmvh$101.7 Bil
REGN
Regeneron Pharmaceuticals IncYbympwvKrbyzw$98.1 Bil
MRNA
Moderna IncPmxspbwrNmwd$38.8 Bil
ARGX
argenx SE ADRMgjcpxcgRfpf$21.7 Bil
BNTX
BioNTech SE ADRRyvvcnlrVscq$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncYdjkqwfQmgkrzp$18.4 Bil
BMRN
Biomarin Pharmaceutical IncWvcmvhbGtwwwgl$17.1 Bil
RPRX
Royalty Pharma PLC Class ABzqhmfrccCcbhdly$12.5 Bil
INCY
Incyte CorpFskhhzpdzFbfxly$11.9 Bil

Sponsor Center